Bin Huang, Ph.D. MBA (Chair)
Dr. Huang is an executive consultant in the Biotech industry. She has been a director of Quest since April 2020 and a director of OncoQuest Inc. since 2015. Dr. Huang was the CEO and director of SpeakEasy Cannabis Club Ltd. from June 2019 to August 2020. She was CEO/President of Emerald Health Therapeutics between 2014 and 2018, President and CEO of WEX Pharmaceuticals between 2007 and 2013, CEO of GeneHarbor Technologies Limited between 2004 and 2006, and President and CEO of Cytovax Biotechnologies Inc. between 1999 and 2004. Dr. Huang has also worked as a biotechnology analyst and was a partner with GMP Securities, a Toronto investment dealer, and has acted as a director of a number of Canadian biotechnology companies and industry associations. Dr. Huang received her PhD in Cell Biology from the University of East Anglia, UK, and her MBA from the University of Toronto, Canada.
W. John Meekison, CPA, CMA, P Log, CIM
Mr. Meekison is a career Chief Financial Officer and investment banker. He has spent the last fifteen years serving in a variety of executive management and CFO roles with both private and public companies, currently serving as the CFO of Exro Technologies Inc. and ArcWest Exploration Inc., both publicly traded companies. Prior to that, Mr. Meekison spent fifteen years in corporate finance with a focus on raising equity capital for North American technology companies, including nine years at Haywood Securities Inc. Mr. Meekison also serves on the board of directors of several public and private companies. Mr. Meekison received his Bachelor of Arts from the University of British Columbia and is a Chartered Professional Accountant, Professional Logistician and Certified Investment Manager.
Shawn Lu, CIM, MFin
Mr. Lu is currently the Chief Financial Officer of Hepalink USA Inc. and has served in this capacity since 2014. From 2013 to 2014, Mr. Lu was employed as the Area Manager for BMO Bank of Montreal in the central Greater Toronto area. From 2005 to 2013, Mr. Lu worked with the TD Bank as a Residential Mortgage Manager in North York, Toronto. From 2001 to 2005, Mr. Lu worked as a senior financial advisor for TD Bank in Toronto. From 1999 to 2000, Mr. Lu was employed with ShenZhen Hepalink Biopharmaceutical Co., Ltd as the CFO and VP of Corporate Finance. From 1998 to 1999, Mr. Lu was employed as the VP of Investment and Corporate Finance with ShenZhen FuTianXin Investment Co., Ltd. From 1992 to 1998, Mr. Lu worked as the General Manager, Corporate finance department, and Manager, Investment and Finance department for China Merchant Shekou Port Co. Ltd. (a ShenZhen Stock Exchange listed company). Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing. Mr. Lu has a Canadian Investment Manager (CIM, Canada) designation and also a Master of Finance Management from Queens University, School of Business, Kingston, Ontario. Mr. Lu also holds a Certified Accountant and Certified Corporate Economist designation in China and has a Master of Corporate Economics and Business Administration from ZhongNan University, Wuhan, China.
Stanley (ki jun) Kim, MBA
Stanley Kim is the CEO and founder of G Company, a Korean biotechnology and medical device company. From 2015 to 2016, Mr. Kim was the Vice Chairman of AT Technology, a semiconductor company. From 2010 to 2017, Mr. Kim was the Vice President of GY Commerce, a B2B platform service company. From 2000 to 2009, Mr. Kim was the founder and CEO of KMH Co., Ltd., a bio-sensor company. From 1994 to 2000, Mr. Kim was the Director of Strategic Business for Samsung Medison, a medical device manufacturer. Mr. Kim has a bachelor’s degree in Biotechnology and an MBA from A-jou University (Korea).